KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Arbutus Biopharma (ABUS) FCF Margin (2016 - 2025)

Arbutus Biopharma's FCF Margin history spans 13 years, with the latest figure at 1099.62% for Q3 2025.

  • For Q3 2025, FCF Margin rose 44900.0% year-over-year to 1099.62%; the TTM value through Sep 2025 reached 310.54%, up 75625.0%, while the annual FY2024 figure was 1053.83%, 57456.0% down from the prior year.
  • FCF Margin for Q3 2025 was 1099.62% at Arbutus Biopharma, down from 146.65% in the prior quarter.
  • Across five years, FCF Margin topped out at 163.29% in Q1 2022 and bottomed at 1548.62% in Q3 2024.
  • The 5-year median for FCF Margin is 613.35% (2021), against an average of 609.92%.
  • The largest annual shift saw FCF Margin skyrocketed 101422bps in 2022 before it plummeted -108026bps in 2024.
  • A 5-year view of FCF Margin shows it stood at 613.35% in 2021, then soared by 55bps to 274.2% in 2022, then crashed by -194bps to 806.15% in 2023, then rose by 18bps to 660.8% in 2024, then tumbled by -66bps to 1099.62% in 2025.
  • Per Business Quant, the three most recent readings for ABUS's FCF Margin are 1099.62% (Q3 2025), 146.65% (Q2 2025), and 759.13% (Q1 2025).